Bortezomib shows promise in patients with previously untreated multiple myeloma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2004年 / 18卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / +
页数：2
相关论文
共 50 条
  • [41] Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
    Yahiya Y. Syed
    Targeted Oncology, 2023, 18 : 303 - 310
  • [42] RESPONSE TO RE-TREATMENT ON RELAPSE MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB
    Rubio-Martinez, A.
    Recasens, V.
    Soria, B.
    Montanes, M. A.
    Rubio-Escuin, R.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 261 - 261
  • [43] Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study.
    Anderson, K.
    Richardson, P.
    Chanan-Khan, A.
    Schlossman, R.
    Munshi, N.
    Oaklander, A.
    Heffner, L.
    Hassoun, H.
    Avigan, D.
    Amato, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 423S - 423S
  • [44] Bortezomib [VELCADE™], pegylated liposomal doxorubicin [DOXIL/CAELYX®] and dexamethasone in the treatment of previously untreated multiple myeloma patients:: Impact on quality-of-life
    Belch, Andrew
    Reece, Donna E.
    Bahlis, Nizar J.
    White, Darrell
    Teixeira, Bruno
    Camacho, Fernando
    Plante, Richard K.
    BLOOD, 2007, 110 (11) : 1058A - 1059A
  • [45] Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma
    Gasparet, Cristina
    Gockerman, Jon P.
    Diehl, Louis F.
    De Castro, Carlos, III
    Moore, Joseph
    Long, Gwynn D.
    Horwitz, Mitchell
    Chute, John
    Sullivan, Keith M.
    Netuwirth, Rachel
    Davis, Patricia H.
    Sutton, Linda M.
    Anderson, Russell D.
    Chao, Nelson
    Rizzieri, David A.
    BLOOD, 2008, 112 (11) : 1142 - 1142
  • [46] "Short Course" Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma
    Gasparetto, Cristina
    Gockerman, Jon P.
    Diehl, Louis F.
    de Castro, Carlos M.
    Moore, Joseph O.
    Long, Gwynn D.
    Horwitz, Mitchell E.
    Keogh, George
    Chute, John P.
    Sullivan, Keith M.
    Neuwirth, Rachel
    Davis, Patricia H.
    Sutton, Linda M.
    Anderson, Russell D.
    Chao, Nelson J.
    Rizzieri, David
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (01) : 70 - 77
  • [47] Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
    Ludwig, Heinz
    Viterbo, Luisa
    Greil, Richard
    Masszi, Tamas
    Spicka, Ivan
    Shpilberg, Ofer
    Hajek, Roman
    Dmoszynska, Anna
    Paiva, Bruno
    Vidriales, Maria-Belen
    Esteves, Graca
    Stoppa, Anne Marie
    Robinson, Don, Jr.
    Ricci, Deborah
    Cakana, Andrew
    Enny, Christopher
    Feng, Huaibao
    van de Velde, Helgi
    Harousseau, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 247 - 255
  • [48] Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    Kumar, Shaji
    Flinn, Ian
    Richardson, Paul G.
    Hari, Parameswaran
    Callander, Natalie
    Noga, Stephen J.
    Stewart, A. Keith
    Turturro, Francesco
    Rifkin, Robert
    Wolf, Jeffrey
    Estevam, Jose
    Mulligan, George
    Shi, Hongliang
    Webb, Iain J.
    Rajkumar, S. Vincent
    BLOOD, 2012, 119 (19) : 4375 - 4382
  • [49] Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy.
    Wang, M
    Delasalle, K
    Giralt, S
    Alexanian, R
    BLOOD, 2005, 106 (11) : 231A - 231A
  • [50] A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
    Hicks, Lisa K.
    Haynes, Adam E.
    Reece, Donna E.
    Walker, Irwin R.
    Herst, Jordan A.
    Meyer, Ralph M.
    Imrie, Kevin
    CANCER TREATMENT REVIEWS, 2008, 34 (05) : 442 - 452
12345